AbbVie Board Recommends Vote Against Shire Deal

The transcript discusses the market's reaction to a failed deal, highlighting the board's recommendation against it and its significance as a major US takeover in Europe. It also examines the impact of the US crackdown on tax inversions, noting increased skepticism and the failure of high-profile inversion attempts like Pfizer-AstraZeneca and Abshire. The challenges of executing such deals due to political opposition and regulatory scrutiny are emphasized.

What is the current status of the deal according to the market?

• The deal is thriving.

• The deal is dead.

• The deal is pending approval.

• The deal is being renegotiated.

What is the main reason for the deal's failure as discussed in the first section?

• Market volatility.

• Regulatory approval issues.

• Board's recommendation against it.

• Lack of investor interest.

What has been the effect of the American crackdown on tax inversions?

• It has stopped many deals.

• It has had no impact.

• It has only affected small deals.

• It has encouraged more deals.

Which two companies' inversion attempts are mentioned as having failed?

• Facebook and Twitter

• Google and Amazon

• Apple and Microsoft

• Pfizer and AstraZeneca

What is a significant challenge in executing large-scale inversion deals?

• Lack of financial resources.

• Political opposition.

• Technological barriers.

• Insufficient market data.